What Cell Biotech does

Cell Biotech Co., Ltd. is a South Korea-based probiotics company founded in 1995 and listed on KOSDAQ under ticker 049960, with headquarters in Gimpo-si, Gyeonggi-do and a wholly-owned European subsidiary in Kongens Lyngby, Denmark. The company operates across three consumer brands — DUOLAC (life-stage-specific probiotic supplements), DUOLAB (enhanced-absorption nutritional supplements), and LACTOClear (skin microbiome cosmetics) — alongside a B2B OEM/ODM service branded LAB2PRO that supplies probiotic raw materials, premixes, strains, and finished products to global partners in 55 countries.

The company's technology platform centers on a worldwide-patented dual-coating technology delivering a clinically demonstrated 100x–221x higher intestinal probiotic survival rate versus uncoated probiotics, combined with Whole Genome Sequencing applied to every commercial strain for safety and functionality validation. Cell Biotech holds FDA GRAS No Objection notices for 11 probiotic strains — claimed as the highest count globally for a single company — and is leveraging its drug delivery system (DDS) and recombinant DNA platform to develop PP-P8, a microbiome-based oral gene therapy for metastatic colorectal cancer currently in Phase I clinical trials at Seoul National University Hospital.

Revenue is generated through consumer product sales (Korean pharmacy and retail channels including Costco Korea and Shinsegae Duty Free, plus overseas retail in Denmark, Singapore, Indonesia, Taiwan, Germany, and China), B2B ingredient and OEM/ODM sales under LAB2PRO, and — prospectively — biopharma milestones from the PP-P8 program. FY2025 consolidated revenue was KRW 53.3 billion with KRW 7.9 billion operating profit, supported by 47 PhD/MS researchers, 231 R&D achievements (124 publications, 107 patents), and 30 years of focused probiotic specialization. The company holds #1 market positions in Korea (top exporter for 12 consecutive years per Korea FDA), Denmark (46.6% share), Singapore, and Indonesia.

Name

Cell Biotech

Legal name

Cell Biotech.,Co.Ltd

Website

https://cellbiotech.com

Company type

Public

Founded year

1995

Operating status

Operating

Headcount range

11–50 employees

Short description

Cell Biotech is a South Korea-based probiotics company (KOSDAQ: 049960) that develops, manufactures, and distributes branded probiotic supplements (DUOLAC, DUOLAB, LACTOClear) and B2B OEM/ODM solutions (LAB2PRO) to 55 countries, while advancing a microbiome-based colorectal cancer drug (PP-P8) through Phase I clinical trials.

Ownership category

akta.pro rank

Product category

Probiotic Supplements and Nutraceuticals

NAICS

Food Manufacturing (311), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Food And Kindred Products (2000), Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Probiotics & Digestive Health Supplements (CRADAGAF)

akta.pro secondary industries

Probiotics (Strains, Spore-Formers, Synbiotic Components) (AFAJAKAE), Probiotic, Prebiotic & Gut-Health Foods Manufacturing (Fermented Functional Foods, Synbiotics) (AFAKAJAH), Probiotic/Fermented Functional Cultured Dairy (Added Cultures/Prebiotics) Manufacturing (AFAHADAJ), Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ)

Keywords

• Probiotic supplements
• OEM/ODM probiotics
• FDA GRAS strains
• Microbiome therapeutics
• Dual coating technology

Headquarters

HQ city

Kimpo

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Branded Probiotic Products (DUOLAC, DUOLAB): Sale of branded probiotic products under DUOLAC (daily care) and DUOLAB (enhanced absorption nutritional supplements) brands. Products include lifecycle-specific probiotics for newborns, children, adults, and menopausal women.
2. OEM/ODM Solutions (LAB2PRO): Complete OEM/ODM service from raw materials to finished products, providing probiotic raw materials, premixes, strains, and ready-to-market solutions tailored to meet diverse needs of global clients.
3. Probiotic Ingredient Sales: Sale of probiotic ingredients to food and dietary supplement manufacturers. 11 strains approved for use at levels up to 1,000,000,000 CFU/serving in dairy products.
4. Functional Probiotic Materials: Sale of scientifically validated probiotic strains and formulations for specific health applications such as cognitive health (MH-Pro with CBT-LR5), kidney health, and other therapeutic uses.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Cell Biotech develops, manufactures and sells probiotic consumer brands (DUOLAC, DUOLAB, LACTOClear), provides end-to-end OEM/ODM probiotic manufacturing services (LAB2PRO), and is developing microbiome-based drug candidates (PP-P8 for colorectal cancer). The company leverages its proprietary dual-coating technology and FDA GRAS-certified strains to deliver probiotic raw materials, premixes, finished products and clinical pipeline assets to global customers.

Product overview

Cell Biotech offers a comprehensive probiotics ecosystem comprising three main consumer brands (DUOLAC, DUOLAB, LACTOClear), an OEM/ODM manufacturing service (LAB2PRO), and a drug development pipeline (PP-P8). DUOLAC is the flagship probiotic brand with life-stage-specific formulations for newborns through adults, built on the company's patented dual-coating technology that ensures 100x higher intestinal survival. DUOLAB provides enhanced-absorption nutritional supplements, while LACTOClear addresses skin microbiome health. LAB2PRO enables B2B partners to access Cell Biotech's probiotic raw materials, strains, and formulation expertise. The company is also pioneering microbiome-based therapeutics with PP-P8, a first-in-class colorectal cancer drug currently in Phase I clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

• DUOLAC: Premium probiotic brand offering scientifically formulated life-cycle tailored products for pregnant women, newborns, infants, children, and adults. Includes DUOLAC Gold, DUOLAC Baby, DUOLAC D-Drops, DUOLAC Yumyum, DUOLAC Gold Capsule, DUOLAC Stop (travel probiotic), DUOLAC Meno Pro (menopausal women), DUOLAC Brain Guard, DUOLAC Slim Pet, DUOLAC The First Class.
• DUOLAB
• LAB2PRO
• LACTOClear

Products and services

• DUOLAC Premium consumer probiotic brand offering life-stage-specific formulations from newborns to adults (including D-Drops, Baby, Yumyum, Gold Capsule, Stop, Meno Pro, Brain Guard, The First Class), built on patented dual-coating technology for 100x higher intestinal survival.
• DUOLAB Enhanced-absorption nutritional supplement brand that combines probiotic formulations with nutrients (e.g., Hyaluronic Acid, biotin, Vitamin C) to improve bioavailability, targeted at inner beauty and gut health.
• LAB2PRO (OEM/ODM) One-stop OEM/ODM probiotic manufacturing service providing raw materials, premixes, strains and ready-to-market finished product solutions, plus marketing and regulatory support, for global B2B partners.
• LACTOClear Skin microbiome brand offering probiotic fermentation-based cosmetic products (e.g., LACTOPAD) for acne care and skin trouble management, with antibacterial properties from natural probiotic fermentation.
• DUOLAC Gold D-Drops Pharmacy-exclusive oil-based probiotic drop formulation for newborns featuring Whole Genome Sequenced, GRAS-registered Bifidobacterium strains and 100% recommended daily intake of vitamin D.
• DUOLAC Brain Guard Cognitive health probiotic product containing clinically validated CBT probiotic strains shown to improve mild cognitive impairment in elderly users.
• DUOLAC Meno Pro Probiotic product targeted at menopausal women over 50 featuring isoflavone-converting equol-producing strains to address hormonal changes, bone density and hot flashes.

Quantifiable outcome

• 221 times higher intestinal survival rate compared to uncoated probiotics
• +5 more outcomes

Named customers4 records

Segments7 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature4 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• Zvezdara University Hospital (Serbia)minorStrategic or Co-development Partner · 2 July 2025Clinical research partnership for CKD (chronic kidney disease) study using CBT Probiotics. Randomized double-blind trial with 34 pre-dialysis patients demonstrating improvements in kidney function markers.
• KALBE (Indonesia)coreChannel Partner/ Reseller/ Distributor · 30 April 2025Strategic partnership with Indonesia's largest pharmaceutical company for distribution and market development of K-probiotics in Indonesian market. KALBE represents key stakeholders for probiotic distribution in Indonesia.
• World Institute of KimchicoreStrategic or Co-development Partner · 18 June 2024Partnership to lead kimchi-derived probiotic research. Cell Biotech will collaborate on developing K-Kimchi Probiotics as colorectal cancer treatment leveraging traditional Korean fermented food-derived probiotic strains.
• Seoul National University HospitalcoreStrategic or Co-development Partner · 21 March 2024Clinical trial partnership for Phase 1 clinical trial of PP-P8 colorectal cancer drug. 32 patients with metastatic colorectal cancer being evaluated for tolerability, safety, and efficacy. Includes dose escalation and dose expansion phases.
• REJIMUS, INC.coreImplementation/ SI/ Consulting Partner · 14 March 2024Regulatory management consultancy guiding Cell Biotech through FDA GRAS notification process. Achieved No Objection notices for 11 probiotic strains, essential for US market entry.
• NAVERminorGTM or Marketing Partner · 3 March 2024Joint business partnership for DUOLAC brand marketing and distribution within Korean digital ecosystem.
• NutraIngredients-AsiaminorGTM or Marketing Partner · 21 February 2022Media partnership for R&D opportunity announcements and probiotic health benefit communications targeting Asian nutrition and health markets.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Chr. Hansen (now Novonesis): Global leader in probiotic strain development and B2B ingredient supply, formed through the 2024 merger of Chr. Hansen and Novonesis. Direct competitor to Cell Biotech's LAB2PRO B2B ingredient business with broader strain portfolio, deeper multinational food/pharma customer relationships, and larger R&D budget.
• DSM-firmenich: Major global probiotics ingredient supplier offering strains for food, beverage, dietary supplement, and infant nutrition applications. Competes directly with Cell Biotech in B2B probiotic ingredients and brings superior scale, regulatory expertise, and integrated solutions across nutrition and health categories.
• Probi AB: Swedish probiotics company specializing in clinically documented probiotic strains with proprietary delivery technology and strong focus on immune and gut health. Direct peer to Cell Biotech in B2B strain supply with similar emphasis on clinical evidence and patented delivery systems.
• Lallemand: Canadian-headquartered global leader in yeast and bacteria-based solutions including probiotic strains for human nutrition, animal health, and supplements. Competes with Cell Biotech in B2B probiotic ingredient supply with established presence across food, dietary supplement, and pharma applications.
• BioGaia: Swedish probiotics specialist focused on clinically proven probiotic products for infant, gut, immune, and oral health. Comparable to Cell Biotech's DUOLAC consumer brand with similar life-stage-specific positioning and emphasis on patented Lactobacillus reuteri strains.
• Lesaffre: Global yeast and fermentation company with a growing probiotics division (including Gnosis by Lesaffre and Bacthera CDMO). Competes with Cell Biotech in both probiotic ingredient supply and contract manufacturing for the human microbiome health market.
• Ganeden (Kerry Group): U.S.-based probiotic ingredient company (acquired by Kerry Group) known for GanedenBC30 (Bacillus coagulans GBI-30) spore-forming probiotic with strong digestive health positioning. Direct competitor to Cell Biotech in B2B ingredient supply with patented shelf-stable technology.
• Winclove Probiotics: Dutch probiotics company specializing in multispecies probiotic formulations for therapeutic applications and B2B ingredient supply. Comparable to Cell Biotech's LAB2PRO model with clinical research emphasis and EU regulatory expertise.

Broad incumbents

• Yakult Honsha: Japanese incumbent in probiotic dairy and supplement products with globally recognized Yakult brand built on Lactobacillus casei strain Shirota. Larger and more established than Cell Biotech, with decades of consumer brand equity and global distribution.
• Morinaga Milk Industry: Japanese dairy major with Bifidobacterium longum BB536 probiotic strain widely used in infant formula and supplements. Comparable to Cell Biotech in probiotic ingredient supply and consumer applications with strong Asian market presence and clinical research heritage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/cell-biotech

Compliance15 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cell Biotech